Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

414 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris.
Eichenfield LF, Hebert AA, Gold LS, Cartwright M, Moro L, Han J, Squittieri N, Mazzetti A. Eichenfield LF, et al. J Drugs Dermatol. 2023 Aug 1;22(8):810-816. doi: 10.36849/jdd.7592. J Drugs Dermatol. 2023. PMID: 37556524 Clinical Trial.
CONCLUSIONS: Clascoterone cream 1% maintained a favorable safety and efficacy profile for up to 12 months in patients aged ≥ 12 years. Eichenfield LF, Hebert AA, Stein Gold L, et al. Long-term safety and efficacy of twice-daily topical clascoterone c …
CONCLUSIONS: Clascoterone cream 1% maintained a favorable safety and efficacy profile for up to 12 months in patients aged ≥ 12 years …
Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry.
Guttman-Yassky E, Bar J, Rothenberg-Lausell C, Eichenfield L, Grada A, Abuabara K, Chapman M, Calimlim B, Wegzyn C, Gamelli A, Krueger W, Munoz B, Knapp K, Faller R, Crawford J, Silverberg J. Guttman-Yassky E, et al. J Drugs Dermatol. 2023 Apr 1;22(4):344-354. doi: 10.36849/JDD.7473. J Drugs Dermatol. 2023. PMID: 37026893
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Paller AS, Flohr C, Eichenfield LF, Irvine AD, Weisman J, Soung J, Pinto Correia A, Natalie CR, Rodriguez Capriles C, Pierce E, Reifeis S, Gontijo Lima R, Armengol Tubau C, Laquer V, Weidinger S. Paller AS, et al. Among authors: eichenfield lf. Dermatol Ther (Heidelb). 2023 Jul;13(7):1517-1534. doi: 10.1007/s13555-023-00942-y. Epub 2023 Jun 15. Dermatol Ther (Heidelb). 2023. PMID: 37318750 Free PMC article.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis.
Jacobson ME, Myles IA, Paller AS, Eichenfield LF, Simpson EL. Jacobson ME, et al. Among authors: eichenfield lf. Dermatology. 2024;240(1):85-94. doi: 10.1159/000532054. Epub 2023 Aug 14. Dermatology. 2024. PMID: 37579728 Clinical Trial.
Use of advanced systemic therapy in patients with moderate-to-severe atopic dermatitis in the TARGET-DERM AD Registry.
Haft MA, Knapp KD, Claxton A, Munoz B, Crawford JM, Balu S, Kim Y, Schneider S, Eichenfield DZ, Silverberg JI, Eichenfield LF, Bagel J, Rhoads JLW, Paller AS. Haft MA, et al. Among authors: eichenfield lf. Curr Med Res Opin. 2024 Dec;40(12):2057-2066. doi: 10.1080/03007995.2024.2427883. Epub 2024 Dec 2. Curr Med Res Opin. 2024. PMID: 39623757
Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years.
Wollenberg A, Ikeda M, Chu CY, Eichenfield LF, Seyger MMB, Prakash A, Angle R, Zhu D, Pontes M, Paller AS. Wollenberg A, et al. Among authors: eichenfield lf. J Dermatolog Treat. 2024 Dec;35(1):2411834. doi: 10.1080/09546634.2024.2411834. Epub 2024 Nov 10. J Dermatolog Treat. 2024. PMID: 39522957 Free article. Clinical Trial.
414 results